This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.
Ranna Eardley-Patel
Advertisement
Ranna Eardley-Patel is a sustainable manufacturing lead at CEPI.
Articles by Ranna Eardley-Patel
Advertisement
Latest Updated Articles
Overcoming Engineering Challenges to Enable Commercial Scale mRNA Vaccine ManufacturingPublished: August 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Everything to Know About Cell and Gene Therapy in 2025
4
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
5
